FDA approves Polatuzumab Vedotin Plus R-CHP for previously untreated DLBCL

FDA approves Polatuzumab Vedotin Plus R-CHP for previously untreated DLBCL
Written by admin

This article originally appeared on OncLive. This version has been slightly modified.

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients with diffuse large B-cell lymphoma ( LDGCB) previously untreated, not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of two or more.1

The regulatory decision converts the June 2019 accelerated approval of the antibody-drug conjugate (ADC) in combination with bendamustine and rituximab (BR) for the treatment of patients with relapsed or refractory DLBCL who have already received at least 2 therapies in regular therapy.2 This approval was based on data from the Phase 1b/2 GO29365 trial (NCT02257567), in which 40% of patients receiving the polatuzumab vedotin regimen achieved a complete response (CR) compared to 18% of patients in the BR arm alone, meeting the primary endpoint criteria of the study.

The first-line approval is supported by results from the Phase 3 POLARIX trial (NCT03274492), in which polatuzumab vedotin plus R-CHP (n=440) significantly improved progression-free survival (PFS) compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=439) in this patient population.3

The addition of ADC to R-CHP resulted in a 27% reduction in the risk of disease progression, relapse or death compared to R-CHOP (HR, 0.73; 95% CI, 0 .57-0.95; P < .02). Data presented at the 2022 Pan Pacific Lymphoma Conference showed that the 2-year PFS rate in the investigational group was 76.7% (95% CI, 72.7%-80.8%) compared to 70.2% in the control group (95% CI, 65.8%-74.6%).

“It has been nearly 20 years since a new treatment option became available for people newly diagnosed with diffuse large B-cell lymphoma,” said Levi Garraway, MD, PhD, Chief Medical Officer and Global Head of products at Roche, in a press release. Press release. “Today’s decision by the FDA to approve Polivy in combination with R-CHP in this setting provides a much-needed new treatment option that may improve outcomes and bring other benefits to many patients with this condition. aggressive lymphoma.”

The international, randomized, double-blind, placebo-controlled POLARIX study enrolled patients with previously untreated LBCL, an International Prognostic Index score between 2 and 5 representing low-to-intermediate-to-high risk disease , no central nervous system disease and no primary large mediastinum B-cell lymphoma.4

The trial included patients with multiple types of LBCL, including DLBCL NOS, HBCL with MYC And BCL2 and or BCL6 rearrangements, HGBL NOS and other low-grade B-cell lymphomas including T cell/histiocyte rich LBCL, Epstein–Barr virus positive DLBCL, ALK-LBCL positive and DLBCL positive for HHV8.

Participants were randomized 1:1 to receive either polatuzumab vedotin 1.8 mg/kg once daily plus rituximab 375 mg/m2, cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 for six cycles 21 days; or R-CHOP standard of care. All patients received 375 mg/m2 rituximab daily for cycles 7 and 8.

Investigator-assessed PFS served as the primary endpoint of the trial. Primary secondary endpoints included event-free survival (EFS), PET-CT CR rate at end of treatment, disease-free survival (DFS), overall survival (OS), and safety.

Additional data showed that the hazard ratio for EFS with polatuzumab vedotin plus R-CHP vs R-CHOP was 0.75 (95% CI, 0.58-0.96; P = .02). No significant difference between the PET-CR rate at the end of treatment was observed (78.0% versus 74.0%; P = 0.16), although DFS data suggest that responses are more durable with the polatuzumab vedotin combination (HR, 0.70; 95% CI, 0.50-0.98).

No significant difference in OS was observed between treatment arms (HR, 0.94; 95% CI, 0.65-1.37; P = 0.75). At a median follow-up of 39.7 months, median OS was not achieved in either arm. At 2 years, the OS rate was 88.7% in both arms.

The toxicity profile of polatuzumab vedotin plus R-CHP was found to be comparable to that of R-CHOP.1 Grade 3 or 4 adverse effects (AE) were experienced by 57.7% of people in the experimental group and 57.5% of those in the control group; serious AEs occurred in 34.0% and 30.6% of patients, respectively. In addition, grade 5 toxicities were reported in 3.0% of people in the ADC group versus 2.3% of those in the placebo group. Toxicities led to dose reductions for 9.2% of those who received polatuzumab vedotin and 13.0% of those who did not.

The most commonly reported toxicities included peripheral neuropathy, nausea, fatigue, diarrhea, constipation, alopecia, and mucositis. Lymphopenia and neutropenia were the most common grade 3 or 4 AEs.

The first-line regulatory approval follows the FDA’s Oncology Drug Advisory Committee vote by 11 to 2 in March 2023 that POLARIX data supports a favorable benefit-risk profile for polatuzumab vedotin in this population.5

The references

  1. (Ad hoc announcement pursuant to Art. 53 LR) FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma. Press release. Rock. April 19, 2023. Accessed April 19, 2023.
  2. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. FDA. June 10, 2019. Accessed April 19, 2023.
  3. Mehta-Shah N, Tilly H, Morschhauser F, et al. Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) before: results of the phase III POLARIX study. Presented at: 2022 Pan Pacific Lymphoma Conference; July 18-22, 2022; Coloa, Hi.
  4. A study comparing the efficacy and safety of polatuzumab vedotin with rituximab-cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with diffuse large B-cell lymphoma (POLARIS). Updated May 31, 2022. Accessed April 19, 2023.
  5. Meeting of the Oncology Drug Advisory Committee (ODAC). Youtube. March 9, 2023. Accessed April 19, 2023.

About the author


Leave a Comment